betadex and Lymphoma--Primary-Effusion

betadex has been researched along with Lymphoma--Primary-Effusion* in 1 studies

Other Studies

1 other study(ies) available for betadex and Lymphoma--Primary-Effusion

ArticleYear
The antitumor effects of methyl-β-cyclodextrin against primary effusion lymphoma via the depletion of cholesterol from lipid rafts.
    Biochemical and biophysical research communications, 2014, Dec-12, Volume: 455, Issue:3-4

    Primary effusion lymphoma (PEL) is a subtype of aggressive and chemotherapy-resistant non-Hodgkin lymphoma that occurs predominantly in patients with advanced AIDS. In this study, we examined the antitumor activity of methyl-β-cyclodextrin (M-β-CyD) in vitro and in vivo. M-β-CyD quickly induced caspase-dependent apoptosis in PEL cells via cholesterol depletion from the plasma membrane. In a PEL xenograft mouse model, M-β-CyD significantly inhibited the growth and invasion of PEL cells without apparent adverse effects. These results strongly suggest that M-β-CyD has the potential to be an effective antitumor agent against PEL.

    Topics: Animals; Antineoplastic Agents; Apoptosis; beta-Cyclodextrins; Cell Survival; Cholesterol; Culture Media; Female; Hemolysis; L-Lactate Dehydrogenase; Lymphoma, Primary Effusion; Membrane Microdomains; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Transplantation; Xenograft Model Antitumor Assays

2014